MediWound Ltd.

AI Score

0

Unlock

19.10
0.81 (4.43%)
At close: Jan 14, 2025, 3:59 PM
19.03
-0.36%
After-hours Jan 14, 2025, 05:23 PM EST
undefined%
Bid 18.75
Market Cap 206.02M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.91
PE Ratio (ttm) -6.56
Forward PE n/a
Analyst Buy
Ask 19.3
Volume 113,974
Avg. Volume (20D) 52,531
Open 18.42
Previous Close 18.29
Day's Range 17.79 - 19.18
52-Week Range 11.04 - 24.00
Beta undefined

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for ...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 20, 2014
Employees 100
Stock Exchange NASDAQ
Ticker Symbol MDWD

Analyst Forecast

According to 1 analyst ratings, the average rating for MDWD stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 30.89% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

MediWound Ltd. is scheduled to release its earnings on Mar 20, 2025, before market opens.
Analysts project revenue of $5.79M, reflecting a 8.47% YoY growth and earnings per share of -0.64, making a 236.84% increase YoY.